15 results about "Auto immune disease" patented technology

The present invention describes novel boron containing pyrazole compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the invention have activity as Janus kinase (JAK) inhibitors and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described are methods of treating inflammation, auto-immune diseases, cancer, and other conditions that are susceptible to the inhibition of a Janus kinase by administering a compound herein described.

The invention relates to a conjugate for transferring an effector molecule from outside a cell into said cell, the conjugate comprising at least one effector molecule to be transferred into the cell, at least one saponin of the mono-desmosidic triterpene glycoside type or the bi-desmosidic triterpene glycoside type, and at least one single-domain antibody (sdAb), covalently bound to each other, wherein the sdAb is capable of binding to a cell-surface molecule of said cell. The invention also relates to a pharmaceutical composition comprising the conjugate of the invention. Furthermore, the invention relates to a pharmaceutical composition of the invention, for use as a medicament. In addition, the invention relates to a pharmaceutical composition of the invention, for use in the treatment or the prophylaxis of any one or more of: a cancer, an auto-immune disease such as rheumatoid arthritis, an enzyme deficiency, a disease related to an enzyme deficiency, a gene defect, a disease relating to a gene defect, an infection such as a viral infection, hypercholesterolemia, primary hyperoxaluria, haemophilia A, haemophilia B, alpha-1 antitrypsin related liver disease, acute hepatic porphyria, an amyloidosis and transthyretin-mediated amyloidosis. The invention also relates to an in vitro or ex vivo method for transferring the conjugate from outside a cell to inside said cell or for transferring the effector molecule comprised by the conjugate of the invention from outside a cell to inside said cell, preferably to the cytosol of said cell.

The present invention pertains to the treatment of diseases associated with a dysregulated immune response such as auto immune disorders, inflammatory diseases or pathological immune responses as adverse effects of medical treatments. In particular the invention provides a combined use of inhibitors of Receptor-interacting serine / threonine-protein kinase (RIPK1) and inhibitors of Inhibitor of κB (IκB) Kinase (IKK) in subjects suffering from such disorders. The invention provides such inhibitory compounds and their combinations for use in medical applications, as well as pharmaceutical compositions comprising the compounds of the invention.

The present invention describes novel boron containing pyrazole compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the invention have activity as Janus kinase (JAK) inhibitors and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described are methods of treating inflammation, auto-immune diseases, cancer, and other conditions that are susceptible to the inhibition of a Janus kinase by administering a compound herein described.

The invention discloses a traditional Chinese medicine composition for eliminating edema, killing cancer cells and improving human immunity, and belongs to the technical field of traditional Chinese medicine preparations. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 8-12 parts of pokeberry root, 2-4 parts of radix euphorbiae lantu, 12-18 parts of poria cocos, 0.3-0.7 part of leech, 25-35 parts of wild buckwheat rhizome, 25-35 parts of polygonum cuspidatum, 25-35 parts of astragalus membranaceus, 10-14 parts of lucid ganoderma, 8-12 parts of glossy privet fruit and 9-13 parts of scutellaria baicalensis. According to the traditional Chinese medicine, the pokeberry root and the radix euphorbiae lantu are used for diminishing swelling and inducing diuresis, the wild buckwheat rhizome and the polygonum cuspidatum are used for killing cancer cells, the astragalus membranaceus, the lucid ganoderma and the glossy privet fruit are used for improving immunity, the poria cocos is used for tonifying spleen and excreting dampness, the leech is used for promoting blood circulation and removing blood stasis, and the scutellaria baicalensis is used for clearing away heat and toxic materials, so that triple effects of eliminating edema, killing cancer cells and reconstructing immune homeostasis are achieved.

The present disclosure relates to a method for producing mesenchymal stem cells for therapeutic applications. The method comprises culturing of MSCs to obtain heterogeneous population. This heterogeneous population of MSCs were subjected to droplet encapsulation media to obtain a population of microfluidic droplets preferably comprising a single MSC; providing the population of microfluidic droplets to a microfluidics device; and identifying and selecting a homogeneous population of MSCs having medium size in the range of 15 to 30 μm showing high expression of cell surface markers (CD73, CD90) and increased expression of genes, such as COL12 A1; IGFBP5; THBS2; GREM1 and CDH2 genes. The MSCs having medium size are further cryopreserved to obtain a cell bank of MSCs with better stability and therapeutic potential in treating diseases like auto immune diseases.

The application generally relates to a therapy comprising at least two therapeutic agents, a first therapeutic compound being an antagonist of IL-7 or CD127 and a second therapeutic compound being an antagonist of IL12, IL-23, IL-12R or IL-23R, or comprising a bifunctional molecule targeting IL-7 or CD127 and IL12, IL-23, IL-12R or IL-23R. The combination therapy or the bifunctional molecule is provided for use in the treatment of a patient suffering from an inflammatory disease or an auto-immune disease.

The present invention relates to novel polycyclic compounds of general Formula (I) wherein X represents N-R5, O, S, or S(O)2; Y represents optionally substituted aryl or heteroaryl; and R1, R2, R3, R4 and R5 represent various groups. The compounds of the invention are useful as inhibitors of the MTHFD2 enzyme, in particular for use in the treatment of diseases associated with MTHFD2 enzyme such as, for example, auto-immune diseases, inflammatory diseases, and proliferative diseases.

The invention relates to novel monoclonal antibodies that bind to human interferon-omega 1 (IFN-ω1), one subtype of type I interferons that play important roles in innate and adaptive immunity. The antibodies can also be used for the diagnosis of auto-immune diseases and viral infections by detecting the presence or level of IFN-ω1 in biological samples. The invention further provides methods of producing the antibodies, nucleic acids encoding the antibodies, and pharmaceutical compositions comprising the antibodies.

Disclosed herein are polypeptides that bind to the epithelial cell adhesion molecule (EpCAM) and programmed death-ligand I (PDL 1) receptors, nucleic acids encoding them, and methods for their use in treating or limited development of cancer, auto immune disease, or inflammation. The disclosure further provides nucleic acids encoding a polypeptide of the disclosure: expression vector comprising a nucleic acid of the disclosure operatively linker to a suitable regulatory control element, host cells comprising a polypeptide, fusion protein, nucleic acid, or expression vector of any embodiment of the disclosure, and pharmaceutical compositions, comprising the polypeptide, fusion protein, nucleic acid, expression vector, or host cell of any embodiment; and a pharmaceutically acceptable carrier.

This invention provides a nitrogen-containing heterocyclic protein inhibitor compound, its stereoisomers, tautomers, or pharmaceutically acceptable salts, and also provides the preparation of nitrogen-containing heterocyclic compounds and their uses. Drugs prepared using these compounds have a wide range of applications in treating diseases, including various types of autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, lupus erythematosus, neurodermatitis, dermatitis, psoriasis, psoriatic arthritis, Crohn's disease, Sjögren's syndrome, and scleroderma.

The invention relates to lipid-based nanoparticles comprising mRNA molecule(s) encoding membrane interleukin 35 (IL-35), and their use to treat inflammatory and / or auto-immune diseases.

The present disclosure relates to a composition comprising a first compound A comprising or consisting of an amino acid sequence of SEQ ID No.: 1 and a low amount of epimer impurities, a method of manufacturing thereof, a compound prepared by said method, an intermediate of said compound, and the use of such composition in medicine, such as in the treatment or prevention of an auto immune disease, diabetes, obesity, parodontitis and / or tissue transplant rejection.

The present disclosure describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. Compounds of the disclosure have activity as dual modulators of Janus kinase (JAK), alone, or in combination with one or more of an additional mechanism, including a tyrosine kinase, such as TrkA or Syk, and PDE4, and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described herein are methods of treating inflammation, auto-immune diseases, cancer, and other conditions susceptible to inhibition of JAK and PDE4 by administering a compound herein described.